Tetra Bio-Pharma (TSX:TBP, OTCQB:TBPMF) Inc. Guy Chamberland talks to Proactive about the significance of the response letter for a Type C meeting with the FDA for its inhaled cannabinoid-based product, QIXLEEF. Chamberland says the FDA has given the group clear guidance, which will allow Tetra to refine its timeliness and budgets to advance and potentially commercialize QIXLEEF.
Tetra Bio-Pharma updates on progress made with inhaled cannabinoid-based product QIXLEEF
